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A B S T R A C T
Mushrooms are important sources of natural bioactive compounds that are increasingly used as cosmeceutical
ingredients. In this context, ethanolic extracts were prepared from Ganoderma lucidum and Pleurotus ostreatus and
tested by incorporation into base cosmetic creams. In vitro safety evaluation of the extracts and cosmetic for-
mulations prepared therefore was carried out using the MTT and LDH assays in keratinocyte (HaCaT) and
ﬁbroblast (HFF-1) cell lines. Moreover, they were submitted to ex vivo skin permeation studies using a Franz
diﬀusion apparatus with pig ear skin as permeation membrane. The results showed the absence of toxicity for
keratinocytes and ﬁbroblasts in a concentration dependent manner, which is indicative of the safety of these
extracts for cosmeceutical ingredients purposes. Protocatechuic and syringic acids were the only compounds
permeating from G. lucidum extract in the ﬁrst 8 h of study, no penetration was observed for phenolic acids found
in P. ostreatus extract and formulation. These results pointed out for the suitability of using mushroom extracts as
skin care ingredients and may contribute for the valorisation of wastes generated by the mushroom processing
industry, which can serve as raw-materials for the obtainment of the extracts.
1. Introduction
The skin is the largest organ of the human body accounting for
about 15% of the total body weight, acting as a barrier between the
internal and the external environment and providing protection against
foreign bodies (Kamble et al., 2017). Extracellular matrix (ECM) of the
skin is the structural support network made up of diverse proteins,
sugars and other components. Some of these structural components
include collagen, elastin, ﬁbronectin, laminin and tenascin hyaluronic
acid. Collectively, these compounds are responsible for maintaining the
tensile strength, cell adhesion, cell migration and wound healing of the
skin (Kular et al., 2014).
Skin care products are generally applied to exert a positive eﬀect on
skin hydration and stabilization of the epidermal barrier. To respond to
a continuous demand for product diversiﬁcation, the global cosmetic
market needs to grow continuously, resulting in the emergence of
products with diﬀerent claims and functional properties (Taoﬁq et al.,
2018, 2016a). Moreover, the rising consumer's consciousness and
awareness about the origin, safety and environmental issues related to
the ingredients used in cosmetic formulations, drives the interest to use
greener and more sustainable raw materials (Rodrigues et al., 2015;
Wang et al., 2015).
Products, either in the form of creams or lotions, and including
biologically active compounds with medical drug-like beneﬁts (Epstein,
2009; Taoﬁq et al., 2016a), are termed "cosmeceuticals". This concept
that gained importance in the last couple of years has rapidly expanded
driven by the enormous availability of novel ingredients of natural
origin (Draelos, 2008). Bioactive extracts from medicinal plants, mi-
crobial metabolites, mushrooms and algae metabolites have been re-
ported to present remarkable bioactive properties (e.g. anti-col-
lagenase, antioxidant, anti-elastase, anti-hyaluronidase, anti-
inﬂammatory and anti-tyrosinase activities) for the development of skin
care formulations (De Wet et al., 2013; Ding et al., 2016; Tamrakar
et al., 2017; Taoﬁq et al., 2018, 2017a).
Mushrooms are globally consumed not only because of their nutri-
tional properties but also for their medicinal potential and richness in
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several bioactive compounds (Heleno et al., 2015; Taoﬁq et al., 2017b,
2016a). Owing to this context, as well as to their increasing use as
nutraceuticals, mushrooms’ market has grown tremendously over the
years (Ferreira et al., 2015; Rathore et al., 2017; Taoﬁq et al., 2017b).
Having in mind the high amount of bio-wastes generated by the related
mushroom processing industry, the need to ﬁnd proﬁtable solutions for
their reuse is of economic, environmental and scientiﬁc interest (Heleno
et al., 2016).
Mushroom cosmeceutical ingredients are gradually entering the
cosmetic market, and this is evident by the number of commercial
cosmeceutical formulations containing mushroom extracts and/or their
bioactive ingredients claiming beneﬁcial eﬀects against ﬁne lines,
wrinkles, ageing, skin texture, photoprotection and pigmentation
(Taoﬁq et al., 2016a; Wu et al., 2016). The evaluation of the derma-
tological potential of new cosmeceuticals comprises the assessment of:
(i) the relevant bioactive properties for the skin; (ii) the penetration
thought stratum corneum and the needed deliver concentration over
time; and (iii) the eﬃcacy and safeness without cytotoxicity, irritation
or sensitization (Levin et al., 2010).
Following studies where the cosmeceutical potential of ethanolic
extracts of Pleurotus ostreatus (Jacq. ex Fr.) P. Kumm) (Taoﬁq et al.,
2018, 2016b) and Ganoderma lucidum (Curtis) P.Karst (Taoﬁq et al.,
2017b). was demonstrated, these extracts were selected for the present
work. Both extracts, obtained by Soxhlet extraction, and their corre-
sponding ﬁnal cosmetic formulations, prepared from a selected based
cream, were tested regarding cell viability and cytotoxic eﬀects using
MTT and LDH assays in keratinocytes (HaCaT) and ﬁbroblasts (HFF-1).
Additionally, the extracts and the ﬁnal formulations were submitted to
skin permeation assays using the Franz diﬀusion cell with pig ear skin
as the permeation membrane.
2. Material and methods
2.1. Mushroom samples
Fresh samples of Pleurotus ostreatus (Jacq. ex Fr.) P. Kumm) were
purchased from a local supermarket in Bragança at the Northeast of
Portugal (41.8061° N, 6.7567° W). For each mushroom species, the
fruiting bodies were dried at 30 °C in an oven and reduced to a ﬁne
powder (20 mesh) for further extraction and analysis. The fruiting
bodies of Gandoderma lucidum (Curtis) P. Karst. were provided by
Bioreishi - Agricultura Biológica, Lda, Portugal (Reishi producers;
Batalha, Portugal) as dry material. The specimens were reduced to
powder (20 mesh). For all the experiments three samples were analysed
and all the assays were carried out in triplicate. The results are ex-
pressed as mean values ± standard deviation (SD).
2.2. Preparation of the mushroom ethanolic extracts
The powdered samples (3.0 g) were extracted with 100mL of
ethanol by reﬂuxing in a Soxhlet apparatus. The obtained extract so-
lutions were ﬁltered through a Whatman paper nº 4 and then dried
under reduced pressure to remove the solvent and recover the solid
extract. The extraction yield was expressed as percentage (%, w/w)
calculated by dividing the weight of the recovered extract (extract, E)
by the weight of the used dry sample.
2.3. Preparation of the base creams added with the extracts
A Versatile™ cream base formulation, free from fragrances, color-
ants, parabens, mineral oils, sodium lauryl sulphate (SLS), propylene
glycol, and ethoxylates was purchased from Fagron Iberica S.A.U.
(Barcelona, Spain). According to the provided technical data, this for-
mulation is certiﬁed to be safe by the US Food and Drug Administration
(FDA), Regulation (EC) No 1907/2006—REACH and the National
Health Surveillance Agency (ANVISA) of Brazil. The cosmeceutical
creams were formulated according to the procedure reported by Taoﬁq
et al. (2016b). Shortly, the base creams were supplemented, separately,
with each extract at a percentage of 2.5% (w/w) corresponding to
25mg per gram base cream. The formulations were mixed properly to
ensure sample homogenisation and then stored in tightly closed vials at
4 °C.
2.4. pH and colour determination
The colour and pH measurements were performed according to the
work of Taoﬁq et al. (2018). Brieﬂy, the colour was measured using a
colorimeter (model CR-400, Konica Minolta Sensing Inc., Tokyo, Japan)
by sampling in three diﬀerent points, and by considering the average as
the true colour value. Colour space values were registered using the
data software “Spectra Magic Nx” (version CM-S100W 2.03.0006). The
pH measurement was measured, in triplicate, directly in the cream with
a HI 99161 pH-meter (Hanna Instruments, Woonsocket, Rhode Island,
USA).
2.5. In vitro evaluation of cell viability and cytotoxic eﬀects in skin cell lines
Two diﬀerent assays were used to assess cell integrity and cyto-
toxicity of the extracts and ﬁnal cosmetic formulations: (1) monitoring
the uptake of the vital mitochondrial dye, 3–(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2–(4-sulfophenyl)-2H-tetrazolium(MTT)
by cell mitochondria and (2) determining the leakage of the cytosolic
enzyme, lactate dehydrogenase (LDH) into the cell medium (LDH
assay). For the cell treatment, samples were dissolved in DMEM and
subsequent dilutions were prepared from 1 μg/mL to 10mg/mL. In both
tests, triplicate wells were incubated with fresh medium in the absence
or presence of samples.
Cell lines and culture conditions. Human immortalized non-tumori-
genic keratinocyte cell line HaCaT (Ethnicity, Caucasian; age, 62 years;
gender, male and tissue, skin) was supplied by CLS Cell Lines Service,
Germany. Human foreskin ﬁbroblasts (HFF-1) were purchased from
ATCC (ATCC Number: SCRC-1041; ATCC, Manassas, VA). Each cell
lines were grown separately in tissue culture ﬂasks (OrangeScientiﬁc,
Belgium). Cell lines were grown in DMEM medium (Carlsbad, CA)
fortiﬁed with L-glutamine, 10% inactivated fetal calf serum (FBS), an-
tibiotic–antimitotic mixture (ﬁnal concentration of 100 U/mL Penicillin
and 100 U/mL Streptomycin) maintained in 5% CO2 incubator (Cell
Culture® CO2 Incubator, ESCO GB Ltd., UK). At 90–95% conﬂuence,
cells were trypsinized and plated in microtiter dishes. The viable cells
were counted using trypan blue dye (Gibco) in hemocytometer.
MTT assay. Cell viability was assessed using the 3-(4,5-di-
methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTT purchased from Promega, Madison, WI) conver-
sion assay. Cells were cultured in 96-well micro titter plate at a density
of 25×103 cells per mL culture medium for 24 h. Then, cells were
incubated with 1 μg/mL–10mg/mL of both extracts and its corre-
sponding formulation, for 24 h at 37 °C. After the removal of samples
from the wells, cells were washed in phosphate-buﬀered saline, fol-
lowed by addition of fresh medium. The micro titter plates were then
incubated in a humidiﬁed atmosphere of 5% CO2 at 37 °C for 24 h. To
evaluate the number of viable cells, 100 μL of MTT solution was added
into each well and incubated for 4 h at 37 °C in the dark. Afterwards, the
medium was removed, the intracellular formazan crystals were solu-
bilized and extracted with 100 μL dimethylsulfoxide (DMSO). After
15min in continuous stirring at room temperature, the absorbance was
measured at 490 nm with background subtraction at 630 nm in a
Synergy HT Microplate Reader (BioTek Instruments, Inc., Winooski,
VT) (Rodrigues et al., 2013).
LDH assay. Brieﬂy, cell lines were seeded in 96-well plates and
cultured for 48 h. Extract and their corresponding formulation at dif-
ferent concentrations was prepared in appropriate medium and added
to the cells. After incubation (37 C/5% CO2), cells were washed twice
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with PBS (pH 7.4) and the LDH kit (Takara Bio Inc., Shiga, Japan) was
used according to the instructions of the manufacturers. To determine
maximum LDH release (high control), some cells were solubilized with
a ﬁnal concentration of 1% (w/v) Triton X-100 (Boehringer
Mannheim). Absorbance was measured at 490 nm with background
subtraction at 690 nm in a Synergy HT Microplate Reader (BioTek
Instruments, Inc., Winooski, VT). Each concentration was tested in
triplicate in three independent experiments (Rodrigues et al., 2013).
2.6. Ex vivo skin permeation studies
Skin model. Porcine ear skin was freshly obtained from a slaughter
house in Porto, Portugal. Preparation of the porcine skin samples con-
sisted of cleaning with water to remove debris and drying them with
paper towels. The prepared skin was protected with aluminium foil and
frozen at−20 °C until required. Before each test, the skin was placed in
0.9% NaCl solution at room temperature for rehydration.
Franz diﬀusion cells. The Franz diﬀusion cell system was used to test
the penetration of compounds present in the ethanolic extract of P.
ostreatus and G. lucidum and their corresponding formulations. A Franz
cell assembly (9mm unjacketed Franz Diﬀusion Cell) comprising a 5-
mL receptor volume and a diﬀusion area of 0.8 cm2 (PermeGear, Inc.
Pennsylvania USA) was used. The skin cells were placed between donor
and the receptor phase with the stratum corneum side facing upward
into the donor compartment. The donor medium consisted of 300 μL
(500 μg/mL) in the case of ethanolic extracts and 100mg of formulation
accurately spread on the skin membrane with the help of a spatula. The
receptor (5mL) was ﬁlled with PBS buﬀer. The stirring rate and tem-
perature of receptor solution were, respectively, kept at 600 rpm and
37 °C. At appropriate intervals (15min, 30min, 45min, 1 h, 2 h, 4 h, 6 h
and 8 h) 600 μL aliquots of the receptor medium were withdrawn with a
syringe and immediately replaced with equal volumes of fresh receptor
phase (Casiraghi et al., 2017). The cumulative quantity of compounds
was determined by HPLC-DAD-ESI/MS.
Chromatographic analysis. Identiﬁcation and quantiﬁcation of in-
dividual triterpenes and phenolic acids were carried out using a Dionex
Ultimate 3000 UPLC system (Thermo Scientiﬁc, San Jose, CA, USA)
previously described by Taoﬁq et al. (2017). Data was collected si-
multaneously with DAD (280 nm) and in negative mode detection on a
Linear Ion Trap LTQXL mass spectrometer (Thermo Scientiﬁc, San Jose,
CA, USA). Xcalibur® data system (Thermo Scientiﬁc, San Jose, CA, USA)
was used for data acquisition. For identiﬁcation, retention times, UV-
VIS and mass spectra were compared with the ones of available stan-
dards. When not available, data from literature was used to tentatively
identify the remaining compounds. Quantiﬁcation was based on cali-
bration curves of available phenolic and triterpenoid standards con-
structed based on the UV signal. Compounds with unavailable com-
mercial standards were quantiﬁed using the calibration curve of the
most similar available standard.
2.7. Statistical analysis
All assays were carried out in triplicate and results were expressed
as mean values and standard deviation (SD). The results were analysed
using one-way analysis of variance (ANOVA) followed by Tukey's HSD
test with α=0.05. A Student's t-test was used to determine the sig-
niﬁcant diﬀerence among two diﬀerent samples, with α=0.05.
Statistical analysis of the results was performed using SPSS v. 23.0
program (IBM Corp., Armonk, New York, USA).
3. Results and discussion
3.1. Description of the developed cosmeceutical formulations
Ethanolic extracts obtained from G. lucidum and P. ostreatus (E1 and
E2, respectively) were incorporated into semi-solid base creams and the
generated formulations designated as F1 and F2 for G. lucidum and P.
ostreatus, respectively. The incorporated extracts may have a positive
eﬀect on the skin when applied topically due to their content in dif-
ferent bioactive molecules (e.g triterpenoids, phenolic acids and related
compounds), as well as the bioactive properties previously reported
(Taoﬁq et al., 2018, 2017b; 2016b). The colour attributes of the pro-
duced formulations in the L*a*b* system were 70.3 ± 0.7,
12.1 ± 0.5, 32.9 ± 0.9 and 88.3 ± 0.5, 0.21 ± 0.02, 19.01 ± 0.4
for F1 and F2, respectively. Both formulations present pH between 3.4
and 4.7 and can be considered adequate for topical application. Natural
extracts, or their individual metabolites, oﬀer many advantages as
cosmeceutical ingredients and are being increasingly used nowadays.
They assume importance not just because of the bioactive potential but
also due to the commercial and market appeal, making them positively
recognized and accepted by consumers.
3.2. Safety of the ethanolic extracts and cosmeceutical formulations
In the present work, the cell viability eﬀect of the ethanolic extracts
prepared from G. lucidum and P. ostreatus was evaluated on HaCaT
(keratinocytes) and HFF-1 (ﬁbroblast) cells, following a concentration
dependent manner (1–10000 μg/mL). Keratinocytes are a biologically
relevant target for skin irritants because they are the ﬁrst living cells
that contact topically with the applied compounds. Also, HaCaT cells
present several morphological and functional features typical of normal
epidermal keratinocytes, making them a good model for skin toxicity
tests (Abruzzo et al., 2017). The chemical proﬁle of the ethanolic ex-
tracts from G. lucidum and P. ostreatus (data not shown) correspond to a
mixture of diﬀerent bioactive compounds, which potentiate the devel-
opment of reactions (allergic or irritant) when applied for dermatologic
purposes, imposing the need to perform cytotoxicity evaluation and
access the minimum concentration reducing the viability of the tested
cell lines.
Regarding HaCaT cells after exposure to both extracts (Fig. 1), up to
90% cell viability was maintained at 100 μg/mL, while the highest
tested concentration (10mg/mL) was found to signiﬁcantly inhibit cell
viability. Concerning HFF-1 cells, the cell viability was maintained up
to 60% at 100 μg/mL for E1, and up to 90% when the same con-
centration was used with E2. Above 100 μg/mL, both extracts were
found to signiﬁcantly aﬀect the viability of HFF-1 cells as shown in
Fig. 2. This result can be used to compare the potential toxicity of the
studied mushroom ethanolic extracts, based on which further experi-
ments can be conducted.
The LDH assay has been utilised as a good marker to ascertain cy-
totoxicity of bioactive ingredients. The mechanism behind it involves
the measurement of lactate dehydrogenase (LDH), an enzyme found in
the surroundings of compromised cell membranes. As shown in Fig. 3,
E2 did not show any potential to cause LDH leakage after exposure to
HaCaT cells. This low toxicity was achieved at 100 μg/mL, more than
50% toxicity was found above 1mg/mL. In what concerns E1, a lower
level of toxicity was found in the range of 4–100 μg/mL, while in-
creased cellular LDH eﬄux was found above 100 μg/mL. Similarly,
Fig. 4 showed that both extracts present low toxicity to HFF-1 cells
between 1 and 10 μg/mL, but increased LDH level was observed be-
tween 100 and 10000 μg/mL for both extracts, comparable to Triton X-
100 (negative control). The results indicate that the ﬁbroblasts cells
were more sensitive when compared to the keratinocytes after exposure
to diﬀerent concentrations of the extracts. These results are in agree-
ment with those obtained for hydroalcoholic extract obtained from the
leaves of six species of Medicago (Rodrigues et al., 2013). The authors
observed that the keratinocytes were more resistant than ﬁbroblasts
when exposed to diﬀerent concentrations of the extract. Based on the
achieved results described, the extract concentration that was able to
maintain cell viability up to 50% can be selected for further experi-
ments or applications.
The ﬁnal cosmeceutical creams formulated with the extracts were
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also submitted to studies evaluating their cell viability on ﬁbroblasts
and keratinocyte cell lines. Data of Fig. 5 indicates that the cell viability
of HaCaT cell lines, after exposure to F1, undergo, up to 60%, main-
tenance of cell viability at 1mg/mL. The eﬀect of F2 on cell viability of
HFF-1 (Fig. 6) showed a cell survival rate of ∼60% for all concentra-
tions below 100 μg/mL, while 1mg/mL and 10mg/mL were found to
be deleterious to the cells. In fact, it is diﬃcult to deduce the cytotoxic
contribution of each component present in the base cream, as well as
the contribution of the individual compounds identiﬁed in the extracts.
To the author's best knowledge, this is the ﬁrst study evaluating the
safety of a ﬁnal cosmetic formulation supplemented with phenolic and
triterpenoid rich extracts obtained from mushrooms.
Most products introduced into the market by cosmeceutical manu-
facturers undergo self-policing since no dedicated regulation for safety
is available. Some of these ingredients can trigger several allergies;
hence, setting up approaches and methods to identify allergens and
evaluate the potential toxicity of some of these products is of huge
importance (Draelos, 2009). The presence of a diversity of chemical
compounds in bioactive extracts may triggers some unwanted skin ir-
ritations, contact dermatitis, photosensitivity, hair and nail damage,
hyperpigmentation, hypopigmentation and systemic eﬀects (Gao et al.,
2008). Since these ingredients are going to be in contact with the skin,
it is vital to evaluate their safety and potential toxicity against skin
cells. Over the years, in vitro models were developed to mimic skin cells
and assess the safety and potential toxicity of bioactive extracts in-
tended for dermatological use (Rodrigues et al., 2013).
3.3. Ex vivo skin permeation
To identify which of the naturally occurring compounds of the
prepared ethanolic extracts from G. lucidum and P. ostreatus were able
to penetrate through the skin, and to evaluate their permeability, ex
vivo experiments were conducted using a pig skin model. From the re-
sults described in Table 1, in what concerns skin penetration proﬁle of
E1, signiﬁcant amounts of compounds were found to penetrate the skin,
but these compounds were not detected in the receptor compartment.
The results showed that a signiﬁcant percentage of the compounds
earlier detected in the extract were retained in the skin layers. It will be
of utmost signiﬁcance if these compounds retained in the skin layers
can elicit a local cosmeceutical eﬀect. Diﬀerent factors such as higher
molecular weight, lipophilicity and aqueous solubility have been re-
ported to be the most important determining factors that explains the
tendency of compounds to permeate or to be retained on the skin sur-
face (Žilius et al., 2013).
Protocatechuic and syringic acids were the unique compounds that
penetrated from the E1 extract suspension through the skin in an
amount that could be quantiﬁed after 8 h, as shown in Table 2. Both
compounds were also detected in the receptor compartment of for-
mulation F1 test. Phenolic acids and related compounds identiﬁed in
the E2 extract are cinnamic, p-hydroxybenzoic and p-coumaric acids,
and none of these compounds were detected in the receptor ﬂuid, up to
8 h of assayed time. This ﬁnding was an indication of the low skin
permeation of extracts prepared from P. ostreatus. Similarly, the
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Fig. 1. Cell viability eﬀects of G. lucidum (E1) and P. os-
treatus (E2) ethanolic extracts on HaCaT cells at diﬀerent
concentrations, as measured by the MTT assay. Values are
expressed as means ± SD (n = 3). Asterisks denote sta-
tistically signiﬁcant diﬀerences compared between the two
extracts in the same concentration (*p < 0.5,
**p < 0.001, ***p < 0.0005). In each extract, diﬀerent
letters mean signiﬁcant diﬀerences between the concentra-
tions (p < 0.05).
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Fig. 2. Cell viability eﬀects of G. lucidum (E1) and P. os-
treatus (E2) ethanolic extracts on HFF-1 cells at diﬀerent
concentrations, as measured by the MTT assay. Values are
expressed as means ± SD (n = 3). Asterisks denote sta-
tistically signiﬁcant diﬀerences compared between the two
extracts in the same concentration (*p < 0.5,
**p < 0.001, ***p < 0.0005). In each extract, diﬀerent
letters mean signiﬁcant diﬀerences between the concentra-
tions (p < 0.05).
O. Taoﬁq, et al. Food and Chemical Toxicology 127 (2019) 228–236
231
penetration and permeation of compounds in formulation F2 was very
low and no compounds were detected in the receptor compartment. The
results showed that the penetration ability of the phenolic acids iden-
tiﬁed in the receptor compartment of the assays with sample E1 and F1
might be due to the enhanced contribution of the high size triterpenes
of E1 and corresponding formulation. Studies have identiﬁed tri-
terpenes, terpenes and sesquiterpenes as promising non-toxic, highly
advanced, non-irritating transdermal penetration enhancers, which
were classiﬁed as generally regarded as safe (GRAS) by the Food and
Drug Administration (Aqil et al., 2007). The results of E1 and F1
samples (Tables 2 and 3) showed that the amounts of compounds
penetrating in the F1 case were higher than the ones of E1 extract
suspension. These results are in agreement with the ones reported by
Tachaprutinun et al. (2014) in which the authors conﬁrmed that the
properties of the base cream (vehicle) have a signiﬁcant impact on the
penetration of the active ingredients.
Bioactive ingredients present in cosmeceutical formulations must be
released from the carrier (base cream) and be able to penetrate the
stratum corneum of the skin in order to deliver a cosmeceutical eﬀect
(Rodrigues et al., 2016). Because of the ban on the use of in vivo assays
for testing cosmetics ingredients, in the cosmetic directive 76/768/EEC
there is a demand for novel in vitro methods to determine the bioa-
vailability of topically applied chemicals (Gerstel et al., 2016). Skin
permeation studies have been conducted in the past using human skin
as membrane, but these experiments are expensive and sometimes
limited due to ethical issues. Penetration studies with human and pig
skin have been conducted and the results have shown that both skin
cells demonstrate positive correlation and bioavailability distribution in
the diﬀerent skin layers with comparable and reproducible results
(Barbero and Frasch, 2009; Diembeck et al., 1999). Histologically many
similarities are observed such as the tissue turnover time, the SC
thickness, the hair-follicle density and the characteristics of their ker-
atinous proteins. However, dissimilarities exist in the level of vascu-
larization, fat component of the SC organized in hexagonal lattice in
pigs and orthorhombic lattice in human (Praça et al., 2018). The goal is
the permeation of active ingredients in stratum corneum, which is po-
pularly referred to as the rate limiting barrier before successfully per-
meating through the epidermis (Haq et al., 2018).
Various types of bioactivities have been reported for triterpenes and
phenolic acids, such as antimicrobial, anti-inﬂammatory and anti-
oxidant properties (Alves et al., 2013; Heleno et al., 2015; Taoﬁq et al.,
2015). In vitro studies have shown that syringic acid present anti-in-
ﬂammatory activity due to the ability to suppress iNOS and COX-2
activity (Lee et al., 2013; Stanikunaite et al., 2009). On the other hand,
protocatechuic acid presents hyperpigmentation potential due to its
ability to inhibit tyrosinase enzyme (Sahin, 2018). Hence, when applied
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posure to extracts E1 and E2. Values are expressed as
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Fig. 4. Cytotoxicity (%) of LDH in HFF-1 cells after exposure
to extracts E1 and E2. Values are expressed as means ± SD
(n = 3). Asterisks denote statistically signiﬁcant diﬀerences
compared between the two extracts in the same concentra-
tion (*p < 0.5, **p < 0.001, ***p < 0.0005). In each
extract, diﬀerent letters mean signiﬁcant diﬀerences be-
tween the concentrations (p < 0.05).
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to the skin, F1 formulation will be able to deliver these potential an-
tioxidant and anti-inﬂammatory compounds for a long period of time as
shown in Table 3. Abla and Banga (2013) have reported the permea-
tion of catechin and resveratrol using porcine ear skin, which was fa-
voured due to the use of propylene glycol that acts as a penetration
enhancer. A more signiﬁcant amount of catechin was retained in the
stratum corneum whereas only 10% was able to be quantiﬁed in the
underlying skin. Other authors suggested that the release of phenolic
compounds from semisolid vehicles is inﬂuenced, not only by the
physiochemical properties of the bioactive ingredient, but also by the
properties of the used vehicle, as well as by the concentration of the
bioactive in the formulation. The above phenomena were reported by
Žilius et al. (2013) after 8 h of ex vivo skin permeation experiments,
where over 90% of the phenolic compounds were released from a hy-
drophilic gel, and only up to 5% and 22% of phenolic compounds were
released from ointment and water-in-oil (w/o) cream, respectively.
These results demonstrated that the E1 ethanolic extract can be utilised
as an ingredient for cosmeceutical application due to the beneﬁcial
biological properties of its individual compounds (protocatechuic and
syringic acids). After topical application, they penetrate the skin, of-
fering advantages as an antioxidative support to the skin, suppressing
oxidative stress and protecting the skin against photo-aging.
4. Conclusion
Presently, there is an awareness of cosmetic users concerning the
used ingredients. Recent market trends involve the use of bioactive
ingredients from natural sources to obtain products with skin beneﬁts
and with less toxic eﬀects. In this study, extracts rich in phenolic
compounds and triterpenoids were obtained from P. ostreatus and G.
lucidum using a Soxhlet extraction system. An in vitro analysis of their
safeness as dermatological ingredients was carried out. The displayed
results are good indicators of extract's suitability for skin care for-
mulations as the absence of toxicity in keratinocytes and ﬁbroblasts is
indicative of their potential safety. The corresponding formulation de-
veloped using the G. lucidum ethanolic extract was able to retain some
of the bioactive compounds, and dermal penetration was detected
mainly for phenolic acids. Comparatively, the skin permeation studies
with the formulation based on P. ostreatus extract showed very low
permeation of their phenolic acids. The results herein justify the con-
tribution of triterpenoids as penetration enhancing ingredients. The
mushroom industry continues to generate large amounts of wastes
during their processing, with these bio-residues available to be used as
inexpensive sources of raw materials for valuable cosmetic ingredients.
Further studies should focus on several novel in vitromodels to evaluate
the safety and toxicity of cosmeceutical ingredients. Also, commercially
available reconstructed human epidermis models such as EpiSkin,
SkinEthic and EpiDerm can be utilised to evaluate the absorption and
permeability of these ingredients, and to test phototoxicity, corrosivity
and irritancy.
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Table 2
Skin permeation proﬁle of the extract E1.
Time Compounds Amount detected in receptor compartment (μg/g)
15min – –
30min – –
45min – –
1 h Protocatechuic acid 51.5 ± 0.4
2 h Protocatechuic acid 35.3 ± 0.2
4 h Protocatechuic acid 11.5 ± 0.1
Syringic acid 37.2 ± 0.4
6 h Protocatechuic acid 12.1 ± 0.1
8 h – –
Each value represents the mean ± SD.
Table 3
Skin permeation proﬁle of the formulation F1.
Time Compounds Amount detected in receptor compartment (μg/g)
15min – –
30min Protocatechuic acid 19.7 ± 0.1
Syringic acid 73 ± 1
45min Syringic acid 66 ± 1
1 h Syringic acid 32.6 ± 0.2
2 h Protocatechuic acid 52 ± 1
Syringic acid 28 ± 1
4 h Syringic acid 46 ± 1
6 h Syringic acid 50 ± 1
8 h – –
Each value represents the mean ± SD.
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